News

Cystic fibrosis (CF) patients show a shift in gut microbiota composition toward more abundant, rarer populations that is significantly associated with antibiotic use, CF disease, and CF-associated changes in gut function and transit, a study shows. These findings add to previous studies showing that CF patients have reduced gut…

Monocyte immune cells from bone marrow partially transplanted into a mouse model of cystic fibrosis (CF) improved survival and reduced inflammation, a study found. Meanwhile, transplanting monocytes from CF mice into healthy mice triggered CF-like symptoms and limited survival, suggesting that these defective immune cells may cause symptoms, the…

The Cystic Fibrosis Foundation has awarded funding to Feldan Therapeutics to develop the Feldan Shuttle, a technology designed to deliver medicines directly inside the epithelial cells that line the airways in people with cystic fibrosis (CF). Awarded as part of the foundation’s $500 million Path to…

Mallory Smith was a poster child for cystic fibrosis (CF). She was a three-sport varsity athlete in high school, was accepted into Stanford University, and was consistent with her therapies, medications, and nutrition. Her smile and positive energy were felt by friends and family. On the inside, however, no…

Poorer growth in childhood is associated with shorter height as adults in people with cystic fibrosis (CF) and does not appear to be linked with nutritional status, a recent study reported. Results of the study, “Most Short Children with Cystic Fibrosis Do Not Catch…

First Wave BioPharma has filed two new patents related to adrulipase, a yeast-derived enzyme that the company is developing to treat exocrine pancreatic insufficiency in people with cystic fibrosis (CF). One application is related to dosage forms, methods of treatment, and manufacturing methods for the investigational medication. This includes a…

The Cystic Fibrosis Foundation has awarded up to $3.5 million to Aceragen to support the clinical development of ACG-701, an investigational antibiotic to treat pulmonary exacerbations in people with cystic fibrosis (CF). “We appreciate the generous support of the Cystic Fibrosis Foundation and are looking forward to…

The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic fibrosis (CF) as young as 6 who have the most common type of CF-causing mutation. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. approved a similar expansion.

Peptilogics has won an award to conduct research for two antibacterial peptides as a first-line therapy to fight antibiotic-resistant bacteria in the lungs of people with cystic fibrosis (CF). According to a press release, the award, by the Cystic Fibrosis Foundation, will support further preclinical research of…

Researchers at The Rockefeller University in New York City have determined how two medications used to treat cystic fibrosis (CF), lumacaftor and tezacaftor, interact with the CFTR protein. The results suggest that these medicines bind to the protein — usually impaired or missing in people with CF — and…